Метастатический кастрационно-резистентный рак предстательной железы и ингибиторы иммунных контрольных точек

Лекарственное лечение некоторых злокачественных новообразований мочеполовой системы претерпело революцию благодаря внедрению в клиническую практику ингибиторов иммунных контрольных точек. Однако применение иммунотерапии при раке предстательной железы несколько ограничено в связи с ее низкой эффективностью. На сегодняшний день пембролизумаб является единственным ингибитором иммунных контрольных точек, одобренным для лечения метастатического кастрационно-резистентного рака предстательной железы (мКРРПЖ) у пациентов с наличием микросателлитной нестабильности или высокой мутационной нагрузкой опухоли. В отношении некоторых комбинаций с ингибиторами иммунных контрольных точек, включающих радиолиганды, лучевую терапию, ингибиторы поли(АДФ-рибоза)-полимеразы, ингибиторы интерлейкина и противораковые вакцины, изучается потенциальный синергетический эффект. Контрольная точка иммунитета B7-H3 является альтернативной, которая может многообещающе дополнить схему лечения мКРРПЖ. Цель обзора – обобщить исследования ингибиторов иммунных контрольных точек в области монотерапии и комбинированной терапии, а также новые стратегии комбинированной иммунотерапии с определением целевых показателей лечения мКРРПЖ.

1. Seer Cancer Statistics. Available at: https://seer.cancer.gov/statfacts/html/prost.html (accessed on 18 March 2023).

2. Mitsogiannis I., Tzelves L., Dellis A. et al. Prostate cancer immunotherapy. Expert Opin Biol Ther 2022;22(5):577–90. DOI: 10.1080/14712598.2022.2027904

3. Claps M., Mennitto A., Guadalupi V. et al. Immune-checkpoint inhibitors and metastatic prostate cancer therapy: learning by making mistakes. Cancer Treat Rev 2020 Aug;88:102057. DOI: 10.1016/j.ctrv.2020.102057

4. Venkatachalam S., McFarland T.R., Agarwal N., Swami U. Immune checkpoint inhibitors in prostate cancer. Cancers (Basel) 2021;13(9):2187. DOI: 10.3390/cancers13092187

5. Iannantuono G.M., Torino F., Rosenfeld R. et al. The role of histology-agnostic drugs in the treatment of metastatic castration-resistant prostate cancer. Int J Mol Sci 2022;23(15):8535. DOI: 10.3390/ijms23158535

6. Pestana R.C., Sen S., Hobbs B.P., Hong D.S. Histology-agnostic drug development – considering issues beyond the tissue. Nat Rev Clin Oncol 2020;17(9):555–68. DOI: 10.1038/s41571-020-0384-0

7. National Comprehensive Cancer Network Guideline Version 1.2023 Prostate Cancer. Available at: https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf (accessed on 18 March 2023).

8. Marabelle A., Le D.T., Ascierto P.A. et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/ mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study. J Clin Oncol 2020;38(1):1–10. DOI: 10.1200/JCO.19.02105

9. Le D.T., Uram J.N., Wang H. et al. PD-1 Blockade in tumors with mismatch-repair deficiency. N Engl J Med 2015;372(26):2509–20. DOI: 10.1056/NEJMoa1500596

10. Antonarakis E.S., Piulats J.M., Gross-Goupil M. et al. Pembrolizumab for treatment-refractory metastatic castration-resistant prostate cancer: multicohort, open-label phase II KEYNOTE-199 study. J Clin Oncol 2020;38(5):395–405. DOI: 10.1200/JCO.19.01638

11. Kwon E.D., Drake C.G., Scher H.I. et al. CA184-043 Investigators. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol 2014;15(7):700–12. DOI: 10.1016/S1470-2045(14)70189-5

12. Beer T.M., Kwon E.D., Drake C.G. et al. Double-blind, phase III trial of ipilimumab versus placebo in asymptomatic or minimally symptomatic patients with metastatic chemotherapy-naive castration-resistant prostate cancer. J Clin Oncol 2017;35(1):40–7. DOI: 10.1200/JCO.2016.69.1584

13. Petrylak D.P., Loriot Y., Shaffer D.R. et al. Safety and clinical activity of atezolizumab in patients with metastatic castration-resistant prostate cancer: a phase I study. Clin Cancer Res 2021;27(12):3360–9. DOI: 10.1158/1078-0432.CCR-20-1981

14. Topalian S.L., Hodi F.S., Brahmer J.R. et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366(26):2443–54. DOI: 10.1056/NEJMoa1200690

15. Powles T., Yuen K.C., Gillessen S. et al. Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trial. Nat Med 2022;28(1):144–53. DOI: 10.1038/s41591-021-01600-6

16. Merck News Release. Available at: https://www.merck.com/news/merck-provides-update-on-phase-3-trials-keynote-641-and-keynote-789/ (accessed on 18 March 2023).

17. Fizazi K., González Mella P., Castellano D. et al. Nivolumab plus docetaxel in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer: results from the phase II CheckMate 9KD trial. Eur J Cancer 2022;160:61–71. DOI: 10.1016/j.ejca.2021.09.043

18. Fizazi K., Ulys A., Sengeløv L. et al. A randomized, double-blind, placebo-controlled phase II study of maintenance therapy with tasquinimod in patients with metastatic castration-resistant prostate cancer responsive to or stabilized during first-line docetaxel hemotherapy. Ann Oncol 2017;28(11):2741–6. DOI: 10.1093/annonc/mdx487

19. Yu E.Y., Kolinsky M.P., Berry W.R. et al. Pembrolizumab plus docetaxel and prednisone in patients with metastatic castration-resistant prostate cancer: long-term results from the phase 1b/2 KEYNOTE-365 cohort B study. Eur Urol 2022;82(1):22–30. DOI: 10.1016/j.eururo.2022.02.023

20. Petrylak D.P., Ratta R., Gafanov R. et al. KEYNOTE-921: phase III study of pembrolizumab plus docetaxel for metastatic castration-resistant prostate cancer. Future Oncol 2021;17(25):3291–9. DOI: 10.2217/fon-2020-1133

21. Petrylak D.P., Ratta R., Matsubara N. et al. Pembrolizumab plus docetaxel for patients with metastatic castration-resistant prostate cancer (mCRPC): Randomized, double-blind, phase 3 KEYNOTE-921 study. J Clin Oncol 2023;41(6_suppl):19. DOI:10.1200/JCO.2023.41.6_suppl.19

22. Sharma P., Pachynski R.K., Narayan V. et al. Nivolumab plus ipilimumab for metastatic castration-resistant prostate cancer: preliminary analysis of patients in the CheckMate 650 trial. Cancer Cell 2020;38(4):489–99.e3. DOI: 10.1016/j.ccell.2020.08.007

23. Sharma P., Krainer M., Saad F. et al. Nivolumab plus ipilimumab for the treatment of post-chemotherapy metastatic castration-resistant prostate cancer (mCRPC): additional results from the randomized phase 2 CheckMate 650 trial. J Clin Oncol 2023;41(6_suppl). DOI: 10.1200/JCO.2023.41.6_suppl.22

24. Heidegger I., Necchi A., Pircher A. et al. EAU-YAU Prostate Cancer Working Party. A systematic review of the emerging role of immune checkpoint inhibitors in metastatic castration-resistant prostate cancer: will combination strategies improve efficacy? Eur Urol Oncol 2021;4(5):745–54. DOI: 10.1016/j.euo.2020.10.010

25. Chen X., Chen F., Ren Y. et al. IL-6 signaling contributes to radioresistance of prostate cancer through key DNA repair-associated molecules ATM, ATR, and BRCA 1/2. J Cancer Res Clin Oncol 2019;145(6):1471–84. DOI: 10.1007/s00432-019-02917-z

26. Mughees M., Kaushal J.B., Sharma G. et al. Chemokines and cytokines: axis and allies in prostate cancer pathogenesis. Semin Cancer Biol 2022;86(Pt 3):497–512. DOI: 10.1016/j.semcancer.2022.02.017

27. Dorff T.B., Goldman B., Pinski J.K. et al. Clinical and correlative results of SWOG S0354: a phase II trial of CNTO328 (siltuximab), a monoclonal antibody against interleukin-6, in chemotherapy-pretreated patients with castration-resistant prostate cancer. Clin Cancer Res 2010;16(11):3028–34. DOI: 10.1158/1078-0432.CCR-09-3122

28. Dorff T., Hirasawa Y., Acoba J. et al. Phase Ib study of patients with metastatic castrate-resistant prostate cancer treated with different sequencing regimens of atezolizumab and sipuleucel-T. J Immunother Cancer 2021;9(8):e002931. DOI: 10.1136/jitc-2021-002931

29. De Bono J., Mateo J., Fizazi K. et al. Olaparib for metastatic castration-resistant prostate cancer. N Engl J Med 2020;382(22):2091–102. DOI: 10.1056/NEJMoa1911440

30. Yu E.Y., Piulats J.M., Gravis G. et al. Pembrolizumab plus olaparib in patients with metastatic castration-resistant prostate cancer: long-term results from the phase 1b/2 KEYNOTE-365 cohort A study. Eur Urol 2023;83(1):15–26. (Erratum in: Eur Urol 2023;83(3):e87). DOI: 10.1016/j.eururo.2022.08.005

31. LeVee A., Lin C.Y., Posadas E. et al. Clinical utility of olaparib in the treatment of metastatic castration-resistant prostate cancer: a review of current evidence and patient selection. Onco Targets Ther 2021;14:4819–32. (Erratum in: Onco Targets Ther 2021;14:5167–8). DOI: 10.2147/OTT.S315170

32. ESMO Congress 2022 OncologyPro. Available at: https://oncologypro.esmo.org/meeting-resources/esmo-congress/pembrolizumab-olaparib-vs-abiraterone-abi-or-enzalutamideenza-for-patients-pts-with-previously-treated-metastaticcastration-resistant-pro (accessed on 18 March 2023).

33. Karzai F., VanderWeele D., Madan R.A. et al. Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations. J Immunother Cancer 2018;6(1):141. DOI: 10.1186/s40425-018-0463-2

34. Bellavia M.C., Patel R.B., Anderson C.J. Combined targeted radiopharmaceutical therapy and immune checkpoint blockade: from preclinical advances to the clinic. J Nucl Med 2022;63(11):1636–41. DOI: 10.2967/jnumed.122.264373

35. Sandhu S., Subramaniam S., Hofman M.S. et al. Evolution: phase II study of radionuclide 177 Lu-PSMA-617 therapy versus 177 Lu-PSMA-617 in combination with ipilimumab and nivolumab for men with metastatic castration-resistant prostate cancer (MCRPC; ANZUP 2001). J Clin Oncol 2023;41(6_suppl):TPS271. DOI: 10.1200/JCO.2023.41.6_suppl.TPS271

36. Czernin J., Current K., Mona C.E. et al. 225Ac-PSMA617 efficacy in a mouse model of prostate cancer. J Nucl Med 2021;62(2):228–31. DOI: 10.2967/jnumed.120.246041

37. Fong L., Morris M.J., Sartor O. et al. A phase Ib study of atezolizumab with radium-223 dichloride in men with metastatic castration-resistant prostate cancer. Clin Cancer Res 2021;27(17):4746–56. DOI: 10.1158/1078-0432.CCR-21-0063

38. Shenderov E., Antonarakis E.S. B7-H3 and prostate cancer: new therapeutic dance partners. Eur Urol 2023;83(3):239–40. DOI: 10.1016/j.eururo.2022.10.019

39. Benzon B., Zhao S., Haffner M. et al. Correlation of B7-H3 with androgen receptor, immune pathways and poor outcome in prostate cancer: an expression-based analysis. Prostate Cancer Prostatic Dis 2017;20:28–35. DOI: 10.1038/pcan.2016.49

40. Guo C., Figueiredo I., Gurel B. et al. B7-H3 as a therapeutic target in advanced prostate cancer. Eur Urol 2023;83(3):224–38. (Erratum in: Eur Urol 2023;83(6):e168–9). DOI: 10.1016/j.eururo.2022.09.004

41. Chapoval A., Ni J., Lau J. et al. B7-H3: a costimulatory molecule for T cell activation and IFN-γ production. Nat Immunol 2001;2:269–74. DOI: 10.1038/85339

42. Kontos F., Michelakos T., Kurokawa T. et al. B7-H3: an attractive target for antibody-based immunotherapy. Clin Cancer Res 2021;27(5):1227–35. DOI: 10.1158/1078-0432.CCR-20-2584

43. Mendes A.A., Lu J., Kaur H.B. et al. Association of B7-H3 expression with racial ancestry, immune cell density, and androgen receptor activation in prostate cancer. Cancer 2022;128(12):2269–80. DOI: 10.1002/cncr.34190

44. Shenderov E., De Marzo A.M., Lotan T.L. et al. Neoadjuvant enoblituzumab in localized prostate cancer: a single-arm, phase 2 trial. Nat Med 2023;29(4):888–97. DOI: 10.1038/s41591-023-02284-w

45. Shi X., Day A., Bergom H.E. et al. Integrative molecular analyses define correlates of high B7-H3 expression in metastatic castrate-resistant prostate cancer. NPJ Precis Oncol 2022;6(1):80. DOI: 10.1038/s41698-022-00323-2

46. Doi T., Patel M., Falchook G.S. et al. 453O DS-7300 (B7-H3 DXd Antibody-Drug Conjugate [ADC]) shows durable antitumor activity in advanced solid tumors: extended follow-up of a phase I/II study. Ann Oncol 2022;33:S744–5. DOI: 10.1016/j.annonc.2022.07.582

47. Jang S., Powderly J.D., Spira A.I. et al. Phase 1 dose escalation study of MGC018, an Anti-B7-H3 Antibody-Drug Conjugate (ADC), in patients with advanced solid tumors. J Clin Oncol 2021;39(15_suppl):2631. DOI: 10.1200/JCO.2021.39.15_suppl.2631

48. Miller J.S., Zorko N., Merino A. et al. 755P B7H3-targeted trispecific killer engagers deliver IL-15 to NK cells but not T-cells, and specifically target solid tumors as a pan-tumor antigen strategy mediated through NK cells. Ann Oncol 2022;33:S889. DOI: 10.1016/j.annonc.2022.07.881

49. Zhang Y., He L., Sadagopan A. еt al. Targeting radiation-resistant prostate cancer stem cells by B7-H3 CAR T cells. Mol Cancer Ther 2021;20(3):577–88. DOI: 10.1158/1535-7163.MCT-20-0446

50. Zorko N., Cichocki F., Goulding J. et al. Preclinical development of multiplexed-engineered IPSC-derived NK cells expressing a novel camelid nanobody Chimeric Antigen Receptor (CAR) targeting pan-cancer antigen B7-H3. Cancer Res 2022;82(Suppl_S12):2761(Abstract). DOI: 10.1158/1538-7445.AM2022-2761